<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG, Biologics Innovation Group. To nurture an Eco-system for Biologics innovation and imprint China on Global map.</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 24 May 2021 19:30:42 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>创药蓝海风向标！BiG七周年即将倚天出鞘</title><link>https://mp.weixin.qq.com/s/_Y7eOYd_W8dsGAYUu3D-0A</link><description></description><content:encoded><![CDATA[创药蓝海风向标！BiG七周年即将倚天出鞘]]></content:encoded><pubDate>Mon, 24 May 2021 17:51:21 +0800</pubDate></item><item><title>近亿元A轮融资！祝贺抗体发现CRO-百英生物</title><link>https://mp.weixin.qq.com/s/Ot8azyC-d1DV4YJlBhwzMA</link><description></description><content:encoded><![CDATA[近亿元A轮融资！祝贺抗体发现CRO-百英生物]]></content:encoded><pubDate>Mon, 24 May 2021 17:51:21 +0800</pubDate></item><item><title>先声药业将于2021 ASCO年会公布多项抗肿瘤药物临床进展</title><link>https://mp.weixin.qq.com/s/bFzDrawgt1LhYmUozBdUSA</link><description></description><content:encoded><![CDATA[先声药业将于2021 ASCO年会公布多项抗肿瘤药物临床进展]]></content:encoded><pubDate>Mon, 24 May 2021 17:51:21 +0800</pubDate></item><item><title>大小开花！君实的生物药管线格局​</title><link>https://mp.weixin.qq.com/s/8-xDlL9Tw1UVZIPuUeAv3Q</link><description></description><content:encoded><![CDATA[大小开花！君实的生物药管线格局​]]></content:encoded><pubDate>Sat, 22 May 2021 22:25:42 +0800</pubDate></item><item><title>第4款双抗获批：来自强生EGFR/cMET</title><link>https://mp.weixin.qq.com/s/b4CNtOLtkZnMEGJLSkgs4Q</link><description></description><content:encoded><![CDATA[第4款双抗获批：来自强生EGFR/cMET]]></content:encoded><pubDate>Sat, 22 May 2021 10:16:59 +0800</pubDate></item><item><title>TACA靶向治疗进展：CAR-T和双抗</title><link>https://mp.weixin.qq.com/s/ZggEWxtG4NMOZDWhQPhpVA</link><description></description><content:encoded><![CDATA[TACA靶向治疗进展：CAR-T和双抗]]></content:encoded><pubDate>Fri, 21 May 2021 19:38:23 +0800</pubDate></item><item><title>ASCO 2021：肿瘤免疫专场的中国声音！</title><link>https://mp.weixin.qq.com/s/zn9kfxSF1uER2sVIJv2k4g</link><description></description><content:encoded><![CDATA[ASCO 2021：肿瘤免疫专场的中国声音！]]></content:encoded><pubDate>Fri, 21 May 2021 19:38:23 +0800</pubDate></item><item><title>BiG七周年｜六十大咖，五百盛会，一场新药蓝海之旅</title><link>https://mp.weixin.qq.com/s/lY9tJKmdu7px3Bj9n_N51A</link><description></description><content:encoded><![CDATA[BiG七周年｜六十大咖，五百盛会，一场新药蓝海之旅]]></content:encoded><pubDate>Thu, 20 May 2021 18:13:58 +0800</pubDate></item><item><title>新药、画展、盲盒、彩蛋...｜BiG慈善之夜来袭</title><link>https://mp.weixin.qq.com/s/mA9styWYcKr3fLxdW_a7Fg</link><description></description><content:encoded><![CDATA[新药、画展、盲盒、彩蛋...｜BiG慈善之夜来袭]]></content:encoded><pubDate>Thu, 20 May 2021 18:13:58 +0800</pubDate></item><item><title>Biotech关口之战，八位研发掌门人即将开辩｜BiG七周年</title><link>https://mp.weixin.qq.com/s/WiIeCtim90m3qAHIUXlpog</link><description></description><content:encoded><![CDATA[Biotech关口之战，八位研发掌门人即将开辩｜BiG七周年]]></content:encoded><pubDate>Wed, 19 May 2021 18:39:16 +0800</pubDate></item><item><title>TIGIT又刷屏了，未来临床应用前景如何？</title><link>https://mp.weixin.qq.com/s/0LzOa68ouT_txlXCzIcZ9A</link><description></description><content:encoded><![CDATA[TIGIT又刷屏了，未来临床应用前景如何？]]></content:encoded><pubDate>Wed, 19 May 2021 18:39:16 +0800</pubDate></item><item><title>天下药物出免疫，还有这些跨界选手</title><link>https://mp.weixin.qq.com/s/2y-hjCdjadbS96wl7tym8A</link><description></description><content:encoded><![CDATA[天下药物出免疫，还有这些跨界选手]]></content:encoded><pubDate>Tue, 18 May 2021 18:28:40 +0800</pubDate></item><item><title>吐槽大会、医药江湖｜BiG会员之夜</title><link>https://mp.weixin.qq.com/s/0JcqoAB4E36qhhRkXlZdCw</link><description></description><content:encoded><![CDATA[吐槽大会、医药江湖｜BiG会员之夜]]></content:encoded><pubDate>Tue, 18 May 2021 18:28:40 +0800</pubDate></item><item><title>大小之间，多肽药物的现实发展与未来展望</title><link>https://mp.weixin.qq.com/s/u2GKwEoIp1zZBzCymy30Rw</link><description></description><content:encoded><![CDATA[大小之间，多肽药物的现实发展与未来展望]]></content:encoded><pubDate>Tue, 18 May 2021 18:28:40 +0800</pubDate></item><item><title>与HER2的天壤之别？HER3究竟能否成药！</title><link>https://mp.weixin.qq.com/s/buweZEaAdlJDea57110GxA</link><description></description><content:encoded><![CDATA[与HER2的天壤之别？HER3究竟能否成药！]]></content:encoded><pubDate>Mon, 17 May 2021 17:59:49 +0800</pubDate></item><item><title>当红炸子鸡KRAS靶点的前世今生</title><link>https://mp.weixin.qq.com/s/waV221dzVsaDmOCqPwhrAw</link><description></description><content:encoded><![CDATA[当红炸子鸡KRAS靶点的前世今生]]></content:encoded><pubDate>Mon, 17 May 2021 17:59:49 +0800</pubDate></item><item><title>一路高歌的康方：梅花香自苦寒来！</title><link>https://mp.weixin.qq.com/s/Px4UfCEWGSHLEwhpqcouGQ</link><description></description><content:encoded><![CDATA[一路高歌的康方：梅花香自苦寒来！]]></content:encoded><pubDate>Sun, 16 May 2021 14:15:39 +0800</pubDate></item><item><title>合成致死赛道的后起之秀：PRMT5/MAT2A抑制剂</title><link>https://mp.weixin.qq.com/s/1KliSNGNF9JzGSb8QxyrPQ</link><description></description><content:encoded><![CDATA[合成致死赛道的后起之秀：PRMT5/MAT2A抑制剂]]></content:encoded><pubDate>Sat, 15 May 2021 08:27:10 +0800</pubDate></item></channel></rss>